Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

T-cell recognizable p53 hotspot mutations offer opportunities for immunotherapy and immune monitoring. Recognition of p53 mutations by peripheral blood CD8 and CD4 T lymphocytes has been revealed.See related article by Malekzadeh et al., p. 1267.

Original publication

DOI

10.1158/1078-0432.ccr-19-3813

Type

Journal article

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research

Publication Date

03/2020

Volume

26

Pages

1203 - 1204

Addresses

Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), Pamplona, Spain.

Keywords

CD4-Positive T-Lymphocytes, Humans, Receptors, Antigen, T-Cell, Antigens, Neoplasm, Immunotherapy, Tumor Suppressor Protein p53